Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate)
Brand Names: Sheffield Triple Antibiotic
Methodology & AI Transparency ⓘ
Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2025-02-17 designates Sheffield Triple Antibiotic (NDC 11527-162, registered by Sheffield Pharmaceuticals LLC) as a over-the-counter branded aminoglycoside antibacterial formulation of Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate.
- 2 Real-world patient consensus: Commercial Sheffield Triple Antibiotic monograph (400 [USP'U]/g / 5000 [USP'U]/g Ointment) cross-indexed with generic Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate for therapeutic equivalence review.
- 3 Typical cash cost range: 30-day cash pricing ranges from $14.66 discount cash to $38.85 walk-in retail (NADAC $0.0856/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate): diarrhea (9.2%), nausea (7.6%), headache (5.1%).
Ask our AI Specialists anything about Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate)
Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2025-02-17 designates Sheffield Triple Antibiotic (NDC 11527-162, registered by Sheffield Pharmaceuticals LLC) as a over-the-counter branded aminoglycoside antibacterial formulation of Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate. Supplied across 400 [USP'U]/g / 5000 [USP'U]/g Ointment; Response-guided Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate dose modification under follow-up, Sheffield Triple Antibiotic is utilized in Uses First aid to help prevent infection in minor: cuts scrapes burns
Clinical pharmacology for Sheffield Triple Antibiotic is driven by Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate acting within aminoglycoside antibacterial signaling cascades with class-characteristic hepatorenal disposition. Distributed across 400 [USP'U]/g / 5000 [USP'U]/g Ointment; Response-guided Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate dose modification under follow-up (NDC 11527-162; registered by Sheffield Pharmaceuticals LLC), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $14.66 to $38.85.
Pharmacokinetic profiling of Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) demonstrates an elimination half-life of Predominantly local clearance at target epithelium for Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) with < 5% transdermal or mucosal systemic uptake from Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) systemic bioavailability; clearance proceeds via local esterase/enzymatic cleavage of sheffield triple antibiotic (bacitracin zinc, polymyxin b sulfate, neomycin sulfate) with minimal hepatic cytochrome burden, reaching clinical onset within initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (sheffield triple antibiotic (bacitracin zinc, polymyxin b sulfate, neomycin sulfate)).
Titration schedules for Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) (400 [USP'U]/g / 5000 [USP'U]/g Ointment → Response-guided Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate dose modification under follow-up) require excluding history of severe allergic sensitivity to sheffield triple antibiotic (bacitracin zinc, polymyxin b sulfate, neomycin sulfate) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2025-02-17 bacitracin zinc, polymyxin b sulfate, neomycin sulfate labeling; real-world patient logs highlight diarrhea (9.2% of reports), nausea (7.6% of reports), headache (5.1% of reports) alongside a 77.00% Worth-It consensus.
Verify medication reconciliation lists so Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) is not inadvertently duplicated with another aminoglycoside antibacterial.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2025-02-17 Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate labeling
Logged Side-Effect Incidence (20 Reports)
Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate))
Human clinical trial evidence for Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0856/unit (~$2.57/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $38.85 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $14.66 / mo | View logs ↓ |
Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) RxNorm Concept ID | 204602-B11527162 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0856 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $38.85 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $14.66 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) integrating DailyMed SPL (2025-02-17), CMS NADAC ($0.0856/unit), and 20 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) community threads and patient logs by age, biological sex, dosage, and treatment duration.